Astrazeneca Buoyed By Huge Paper Profit On Stake In Coronavirus Vaccin
Astrazeneca Buoyed By Huge Paper Profit On Stake In Coronavirus Vaccine Company Moderna
Astrazeneca, the British pharmaceuticals giant that is currently the UK’s most valuable public company, is sitting on a major ‘paper profit’, on its 7.7% stake in Moderna, the Massachusetts-based drugs company at the front of the queue to provide a Covid-19 vaccine. Having invested an initial $240 million in Moderna in 2013, topped up by $140 million in 2016, Astrazeneca’s stake is now worth over $2 billion.